Neurology
MOGAD Is Close to Its First Real Treatment
FDA Priority Review for satralizumab puts MOGAD within reach of its first specifically approved disease-modifying therapy. For a disease built around unpredictable neurological attacks, the distinction matters.
Tourette Care May Finally Get a New FDA Test
Dementia Is Not the End of Personhood
Narcolepsy Treatment Starts Targeting the Cause
Optic Neuritis Moves Into the Neuroprotection Race
Huntington’s Gene Therapy Moves Back Toward the FDA Door
Alzheimer’s Research Moves Beyond Amyloid
Cellular Reprogramming Enters Neuro-Ophthalmology
Alzheimer’s Agitation Moves Closer to a Phase 2 Readout
ALS Survival Data Return to the Evidence Debate
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases